This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Ludwig Institute for Cancer Research Limited, Paracrine Therapeutics Ab. Active years: 2006-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Stockholm, SE (2006)
- Sollentuna, SE (2022)
Company Filing History:
1 out of 530 
1 out of 2 Years Active: 2006-2022
Title: Innovations by Inventor Hong Li in PDGF-C Research
Introduction
Hong Li is a prominent inventor based in Sollentuna, Sweden, known for his contributions to medical research and innovation. With two patents to his name, he has developed significant advancements in the understanding and treatment of diseases associated with platelet-derived growth factor C (PDGF-C).
Latest Patents
Hong Li's latest patents reflect his dedication to advancing medical science. The first patent, titled "Methods and Compositions for PDGF-CC Inhibition," focuses on isolated antibodies that specifically interact with an epitope of PDGF-C. These antibodies have the potential to modulate PDGF-C activity, aiding in the study of cell functions and offering possibilities for treating diseases related to PDGF-C signaling pathways.
The second patent, "Non-Human Transgenic Animals Expressing Platelet-Derived Growth Factor C (PDGF-C) and Uses Thereof," introduces non-human transgenic animals that overexpress PDGF-C. These animals serve as valuable models for studying disease states characterized by the overexpression of PDGF-C and evaluating potential therapies aimed at such conditions.
Career Highlights
Throughout his career, Hong Li has collaborated with esteemed institutions to further his research. Notably, he has worked with the Ludwig Institute for Cancer Research Limited and Paracrine Therapeutics AB. His work has played a crucial role in enhancing our understanding of PDGF-C’s impact on cell behavior and its implications in various diseases.
Collaborations
Hong Li has collaborated with notable researchers such as Ulf Eriksson and Xuri Li. These partnerships have facilitated the advancement of innovative research in the field of cancer and regenerative medicine, fostering a collaborative environment that enriches the scientific community's understanding of PDGF-C.
Conclusion
Hong Li’s contributions to the understanding of PDGF-C not only enhance scientific knowledge but also pave the way for potential therapeutic interventions in diseases linked to this growth factor. His patents underscore the importance of innovation in medical research and illustrate the profound impact that dedicated inventors can have on healthcare advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile